Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search
Search results
BBC Lifeline Appeal 2025
During our 50th anniversary year, Retina UK was the focus of a BBC Lifeline Appeal on Sunday 16 November 2025.
Retina UK set to feature in BBC Lifeline Appeal
Catch up on our BBC Lifeline Appeal from November 2025.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
e-Newsletter October 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
E-Newsletter June 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.